The Swedish Pavilion at BIO International 2026
 |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |
Co-organizers and Partners
Welcome to Business Sweden – the Swedish Trade & Invest Council. We help Swedish companies grow global sales and international companies invest and expand in Sweden. Business Sweden is jointly owned by the Swedish state and the business sector. Our team of advisors and industry experts provide insights, strategic guidance, and hands-on support in more than 40 locations worldwide.
SwedenBIO is the national trade organization for life sciences in Sweden. Our member companies develop biotechnology, diagnostics, pharmaceuticals and medical devices or are experts in business development, IP and law, among others. We also bring together financiers, incubators, science parks, regional investment promoters and many more.
Invest in Skåne is the official investment promotion agency in Sweden’s southernmost region – Skåne. We provide professional advice and services to international companies considering Skåne for future investments and expansions. Invest in Skåne is part of the department for Regional Development at Region Skåne.
Business Region Göteborg AB (BRG) is the economic development agency and investment promotion agency of Gothenburg. Our mission is to contribute to high employment, investments, and a diversified business sector with a focus on long-term sustainable development in the Gothenburg region.
The Consulate General of Sweden in San Francisco represents Sweden in California and Hawaii. Its mission is to provide assistance to Swedes and to promote Swedish interests. The section for Trade and Export promotion works with trade, export- and business related activities with the purpose of promoting the exchange between Sweden, California, and Hawaii.
SACC San Diego is a dynamic business organization serving as the gateway for companies and professionals interested in the San Diego and Swedish business environments. We provide essential business services to both Swedish and American companies and professionals, organize high-profile networking events, and deliver valuable opportunities to our members and their ventures.
AstraZeneca is a global, science-led, patient-focused pharmaceutical business. We are committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life.
The DNB Carnegie | Back Bay Partnership strengthens companies with financial and strategic guidance on growth opportunities across sector and development stage. We are a committed partner throughout the development journey, addressing positioning, partnering, financing, M&A strategies, and listing support and execution on U.S. and Nordic exchanges.
Participating companies
Atrogi is a Phase II-ready biotech company pioneering oral therapies that preserve and build muscle. Our lead compound ATR-258 delivers healthy weight loss with preservation of lean muscle mass and improvement in muscle function—working as a standalone therapy or in combination with appetite suppressants. With Phase I complete, strong safety data, and 6-month toxicology studies done, we are ready to advance into Phase II. Our proprietary platform of 1,000+ biased β2-receptor modulators enables pipeline expansion into sarcopenia, healthy aging, DMD, FSHD, and other muscle wasting diseases.
Your Special Delivery Service (YSDS) is an international logistics company specializing in seamless global shipping solutions for extraordinary products, destinations and timeframes. Through our team of dedicated and professional shipping professionals, we provide high-quality logistics consulting and execution mainly in the fields of Life Science, IT/Tech and Industrial.
Orexo is a pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development.
NOSA is a Swedish Life Science company specialized in intra nasal breathing devices. The company is present in 20+ markets and sells more than 8 million products a year. NOSA has a patented technology that enables slow release of APIs through its nasal inserts "NOSA Cerevia". The technology provides a release of the API in gaseous form which enables an effective absoption through the olfactory bulb and the trigeminal nerve and by doing so bypassing the blood-brain-barrier. The technology is proven and shows high doses in blood and brain plasma. NOSA Cerevia is available for licensing.
BioArctic is a Swedish research-based biopharma company focusing on generating innovative drugs that improve the lives of patients with disorders of the central nervous system. We develop drugs with the potential to revolutionize the treatment of disorders such as Alzheimer’s disease, Parkinson’s disease, ALS and Huntington, as well as advanced technology to facilitate the passage of different modalities across the blood-brain barrier. To expand the opportunities for value creation, we collaborate closely with leading academic research groups and companies in the global pharma industry.
Envirotainer transports life-saving pharmaceuticals around the world with innovative temperature-controlled solutions. With 40 years leading the industry, the world's largest pharmaceutical companies trust us to deliver. We offer the widest choice of cold chain solutions with a range of shipment monitoring services, all backed by our extensive global network to get your product to where it needs to be, precisely when it needs to be there.
Xinnate AB is a Swedish biotech developing TCP-25, a first-in-class peptide with a novel, well-documented mode of action published in leading journals including Nature Communications and Science Translational Medicine. TCP-25 uniquely combines anti-inflammatory and anti-infective effects, optimizing healing, reducing exudation and improving skin function. The lead asset, TCP-25 gel for Epidermolysis Bullosa, has completed Phase 1 including DEB patients, demonstrating strong safety and promising exploratory efficacy. A global pivotal Phase 2/3 study (STEP) is ongoing.
Sever Pharma Solutions is a full-service CDMO specializing in advanced polymer drug products and packaging, including high-potent APIs. We focus on cost-efficient development and reliable large-scale production of high-value products. Our experts in polymers and extrusion design robust, scalable delivery systems, supported by a dedicated Hot Melt Extrusion team in the USA.
OnDosis is an AstraZeneca spin out founded in 2017 and headquartered in Sweden. The company is developing a first in category Dosage Manager, a connected handheld device platform technology for precise and flexible dosing of oral solid medicines, formulated as multiparticulates (granules, pellets, powders or mini tablets). The OnDosis solution overcomes challenges in complex dosing when traditional dosage forms are not good enough.
AlzeCure® Pharma is a spin-out from AstraZeneca and a Swedish clinical stage biotech developing new innovative small molecule drug therapies for severe diseases & conditions that affect the central nervous system, such as Alzheimer’s disease and neuropathic pain. AlzeCure is listed at Nasdaq First North Premier Growth Market in Sweden and is developing several parallel drug candidates based on three research platforms: NeuroRestore® (Trk-PAM), Alzstatin® (Gamma-Secretase Modulators) and Painless (TrkA-NAM & TRPV1-antagonist). We are supported by the European Innovation Council.
The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others. Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna.
At Omnio, we harness the unique power of plasminogen to unlock new therapies for chronic wounds and inflammation. Starting with diabetic foot ulcers, our biologically driven platform is paving the way toward better healing, reduced scarring, and a future free from persistent infections. Our therapy is built on decades of research at Umeå University, where Professor Tor Ny uncovered the essential role of plasminogen in wound healing. Now, our team expands from Sweden, to Spain, the UK, Denmark and India. We are getting ready to perform our phase IIa/b trials in 2026 and 2027.
Sprint Bioscience develops innovative drug candidates that enable new cancer treatments. Using our expertise in fragment-based drug development, we accelerate early programs efficiently, delivering high-quality candidates quickly and with optimal resources. With a broad portfolio, we maximize success and advance multiple programs in parallel. We specialize in the pre-clinical stage, partnering to move projects through regulatory development and rapidly translate science into potential therapies.
AcuCort has developed and is commercializing Zeqmelit®, a fast-dissolving oral film containing the glucocorticoid dexamethasone. Launched in Sweden, Denmark, Norway and Finland, Zeqmelit®'s indications include the treatment of acute and severe allergic reactions, acute severe asthma, croup in children, nausea and vomiting during chemotherapy and the treatment of COVID-19 patients with breathing difficulties and need for oxygen therapy. AcuCort partners with leading regional or global players with market presence, expertise and resources to launch rapidly after regulatory approval.
AWA is a leading intellectual property firm with over 400 employees across 20+ offices in Belgium, China, Denmark, Hong Kong, Norway, Sweden and Switzerland. Our clients are innovative companies, ranging from local start-ups to global giants. Our IP professionals are experts in patents, trademarks, designs, copyright, and domain names – all as passionate about your innovations and brands as you are. AWA was founded in 1897 by the Swedish engineer Anders Wilhelm Anderson. His initials form our company name and remind us of our proud history and the experience we bring to all our clients.